Lack of progression of brain abnormalities in first-episode psychosis: a longitudinal magnetic resonance imaging study
Carregando...
Citações na Scopus
54
Tipo de produção
article
Data de publicação
2011
Editora
CAMBRIDGE UNIV PRESS
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
LAPPIN, J. M.
UCHIDA, R. R.
SANTOS, L. C.
MURRAY, R. M.
MCGUIRE, P. K.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
PSYCHOLOGICAL MEDICINE, v.41, n.8, p.1677-1689, 2011
Resumo
Background. Some neuroimaging studies have supported the hypothesis of progressive brain changes after a first episode of psychosis. We aimed to determine whether (i) first-episode psychosis patients would exhibit more pronounced brain volumetric changes than controls over time and (ii) illness course/treatment would relate to those changes. Method. Longitudinal regional grey matter volume and ventricle : brain ratio differences between 39 patients with first-episode psychosis (including schizophrenia and schizophreniform disorder) and 52 non-psychotic controls enrolled in a population-based case-control study. Results. While there was no longitudinal difference in ventricle : brain ratios between first-episode psychosis subjects and controls, patients exhibited grey matter volume changes, indicating a reversible course in the superior temporal cortex and hippocampus compared with controls. A remitting course was related to reversal of baseline temporal grey matter deficits. Conclusions. Our findings do not support the hypothesis of brain changes indicating a progressive course in the initial phase of psychosis. Rather, some brain volume abnormalities may be reversible, possibly associated with a better illness course.
Palavras-chave
First-episode psychosis, longitudinal study, schizophrenia, ventricular volume, voxel-based morphometry
Referências
- American Psychological Association(APA), 1994, DIAGN STAT MAN MENT
- Theberge J, 2007, BRIT J PSYCHIAT, V191, P325, DOI 10.1192/bjp.bp.106.033670
- Lieberman JA, 2005, ARCH GEN PSYCHIAT, V62, P361, DOI 10.1001/archpsyc.62.4.361
- Honea R, 2005, AM J PSYCHIAT, V162, P2233, DOI 10.1176/appi.ajp.162.12.2233
- Sun D, 2009, MOL PSYCHIATR, V14, P976, DOI 10.1038/mp.2008.34
- van Haren NEM, 2008, BIOL PSYCHIAT, V63, P106, DOI 10.1016/j.biopsych.2007.01.004
- KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261
- Nakamura M, 2007, BIOL PSYCHIAT, V62, P773, DOI 10.1016/j.biopsych.2007.03.030
- Glantz LA, 2006, SCHIZOPHR RES, V81, P47, DOI 10.1016/j.schres.2005.08.014
- Wright IC, 2000, AM J PSYCHIAT, V157, P16
- DeLisi LE, 2004, PSYCHIAT RES-NEUROIM, V130, P57, DOI 10.1016/j.pscychresns.2003.08.004
- Bookstein FL, 2001, NEUROIMAGE, V14, P1454, DOI 10.1006/nimg.2001.0770
- Lieberman J, 2001, BIOL PSYCHIAT, V49, P487, DOI 10.1016/S0006-3223(01)01067-8
- Puri BK, 2001, PSYCHIAT RES-NEUROIM, V106, P141, DOI 10.1016/S0925-4927(01)00072-5
- Menezes NM, 2006, PSYCHOL MED, V36, P1349, DOI 10.1017/S0033291706007951
- McGlashan TH, 2006, SCHIZOPHRENIA BULL, V32, P609, DOI 10.1093/schbul/sbl032
- Pantelis C, 2005, SCHIZOPHRENIA BULL, V31, P672, DOI 10.1093/schbul/sbi034
- Smieskova R, 2009, CURR PHARM DESIGN, V15, P2535
- Wood SJ, 2008, SCHIZOPHRENIA BULL, V34, P322, DOI 10.1093/schbul/sbm149
- Zipursky RB, 2004, SCHIZOPHR RES, V71, P515, DOI 10.1016/j.schres.2004.02.028
- Gur RE, 1998, ARCH GEN PSYCHIAT, V55, P145, DOI 10.1001/archpsyc.55.2.145
- Kasai K, 2003, AM J PSYCHIAT, V160, P156, DOI 10.1176/appi.ajp.160.1.156
- Mane A, 2009, SCHIZOPHR RES, V114, P136, DOI 10.1016/j.schres.2009.07.014
- DeLisi LE, 2008, SCHIZOPHRENIA BULL, V34, P312, DOI 10.1093/schbul/sbm164
- Scott L, 2009, NEUROSCIENCE, V158, P62, DOI 10.1016/j.neuroscience.2008.10.020
- Kubicki M, 2002, NEUROIMAGE, V17, P1711, DOI 10.1006/nimg.2002.1296
- Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786
- Navari S, 2009, PSYCHOL MED, V39, P1763, DOI 10.1017/S0033291709005315
- Cahn W, 2009, EUR NEUROPSYCHOPHARM, V19, P147, DOI 10.1016/j.euroneuro.2008.10.006
- Lieberman JA, 1999, BIOL PSYCHIAT, V46, P729, DOI 10.1016/S0006-3223(99)00147-X
- Kasai K, 2003, ARCH GEN PSYCHIAT, V60, P766, DOI 10.1001/archpsyc.60.8.766
- Toro CT, 2007, SCHIZOPHR RES, V90, P1, DOI 10.1016/j.schres.2006.09.030
- Keshavan MS, 1998, J PSYCHIAT RES, V32, P161, DOI 10.1016/S0022-3956(97)00038-1
- Kennedy KM, 2009, NEUROBIOL AGING, V30, P1657, DOI 10.1016/j.neurobiolaging.2007.12.020
- Ho BC, 2003, ARCH GEN PSYCHIAT, V60, P585, DOI 10.1001/archpsyc.60.6.585
- Cahn W, 2002, ARCH GEN PSYCHIAT, V59, P1002, DOI 10.1001/archpsyc.59.11.1002
- DeLisi LE, 2005, PSYCHIAT RES-NEUROIM, V138, P265, DOI 10.1016/j.pscychresns.2005.02.005
- First MB, 1995, STRUCTURED CLIN INTE
- HULSHOFF PHE, 2001, ARCH GEN PSYCHIAT, V58, P1118
- Kasparek T, 2009, PROG NEURO-PSYCHOPH, V33, P1438, DOI 10.1016/j.pnpbp.2009.07.025
- Koo MS, 2008, ARCH GEN PSYCHIAT, V65, P746, DOI 10.1001/archpsyc.65.7.746
- Lappin Julia M, 2007, Br J Psychiatry Suppl, V51, ps123, DOI 10.1192/bjp.191.51.s123
- Menezes Paulo R, 2007, Br J Psychiatry Suppl, V51, ps102, DOI 10.1192/bjp.191.51.s102
- Price G, 2006, SCHIZOPHR RES, V87, P100, DOI 10.1016/j.schres.2006.06.019
- Schaufelberger Maristela S, 2007, Br J Psychiatry Suppl, V51, ps117, DOI 10.1192/bjp.191.51.s117
- Talairach J., 1988, COPLANAR STEREOTAXIC
- Tanskanen P., 2008, SCHIZOPHR B, V36, P766
- Whitworth AB, 2005, PSYCHIAT RES-NEUROIM, V140, P225, DOI 10.1016/j.pscychresns.2005.07.006
- Wood SJ, 2001, SCHIZOPHR RES, V52, P37, DOI 10.1016/S0920-9964(01)00175-X